We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · June 06, 2020

Maintenance Pembrolizumab After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
J. Clin. Oncol 2020 Jun 01;38(16)1797-1806, MD Galsky, A Mortazavi, MI Milowsky, S George, S Gupta, MT Fleming, LH Dang, DM Geynisman, R Walling, RS Alter, M Kassar, J Wang, S Gupta, N Davis, J Picus, G Philips, DI Quinn, GK Haines, NM Hahn, Q Zhao, M Yu, SK Pal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading